Search

everythinglearnresearchcommunity

for

Search:↓

A new gel form of minoxidil is equally effective for hair growth and safer for the heart and other organs than the traditional solution.

Longer anogenital distance may indicate a higher chance of having polycystic ovary syndrome, and measuring this distance along with hormone levels could improve diagnosis.

Alopecia in animals can be hereditary, congenital, or acquired, with treatments and outcomes varying widely.

A genetic test can identify people at risk of male pattern baldness early, allowing for quicker treatment.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Selenium and vitamin E supplements have mixed effects on prostate cancer risk and may not be beneficial for everyone.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Prostate cells have proteins that bind to specific hormones, which can increase protein production when activated by these hormones.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Large prostate links to more hair loss, but age of onset doesn't affect it.

Men who start losing hair at age 30 may have a lower risk of prostate cancer.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Hair loss gene linked to prostate issues.

Monascus helps prevent baldness, prostate issues, and may be a natural alternative to medications.